-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Treatment, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Myasthenia Gravis market through 2034. The MG market across the 7MM was valued at $4.5 billion in 2024 and is expected to grow to $13.0 billion by 2034 at a compound annual growth rate (CAGR) of 11.1%. The US represents the largest market for MG, with roughly 75.4% of sales across the seven major markets (7MM)—the US, France, Germany, Italy, Spain, the UK, and Japan—in...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, July 2026
Why Does Bio/Pharmaceutical Outsourcing Matter? Bio/pharmaceutical outsourcing plays an important role in pharmaceutical manufacturing, with contract manufacturing organizations (CMOs) responding to changing demand, regulatory requirements, technology investment, and supply chain dynamics. This monthly report provides analysis of the latest business conditions and developments affecting the pharmaceutical outsourcing industry. It tracks outsourcing contracts, CMO mergers and acquisitions, financing, facility openings and closures, GMP inspections, technology investments, supply chain challenges, and emerging opportunities and threats. You can use this report to: Monitor...
-
Sector Analysis
Tuberous Sclerosis Complex (TSC): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Tuberous Sclerosis Complex (TSC) Therapeutics. In 2025, there were 198,627 diagnosed prevalent cases of TSC-associated epilepsy in the 16 countries covered in GlobalData’s epidemiology forecast. In 2021, the most recent updated guidance for physicians for the diagnosis and treatment of TSC was established by the International TSC Consensus Group. In addition to the international consensus, country- or region-specific guidelines are available for selected TSC manifestations. TSC...
-
Sector Analysis
Major Depressive Disorder: Epidemiology Report and Forecast to 2035
Major depressive disorder (MDD), also known as clinical depression, represents one of the most pervasive and debilitating mental health conditions globally. MDD is clinically defined by a constellation of cognitive and physical symptoms persisting for at least two weeks, as established by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) (American Psychiatric Association, 2026). MDD is a complex, multifaceted medical illness characterized by persistent depressed mood, anhedonia, recurrent thoughts of death, and physical and cognitive symptoms. MDD can severely...
-
Sector Analysis
Chronic Kidney Disease in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the chronic kidney disease (CKD) market through 2035. GlobalData estimates the sales of CKD therapeutics to be approximately $4.3 billion across the 7MM in 2025. By 2035, GlobalData expects the CKD market to grow at a strong compound annual growth rate (CAGR) of 9.8%, reaching sales of $10.9 billion by the end of the forecast period. The major drivers of CKD market growth over the...
-
Sector Analysis
Ireland in the IRP Crossfire
Ireland's decision to exclude the UK from its international reference pricing (IRP) basket from 2027 will exert mild downward pressure on achievable ex-manufacturer prices for innovative medicines, a GlobalData analysis of POLI data across 22 recently reimbursed products finds.
-
Thematic Analysis
Global M&A Deals in H1 2026 - Top Themes by Sector: Strategic Intelligence
Why Does M&A Activity Matter? Mergers and acquisitions can provide a view into the themes reshaping industries and where companies are directing capital and strategic investment. The global M&A market recorded $1.7 trillion in deal value in H1 2026, up 47% from H1 2025. This report analyzes the most notable transactions across major sectors and identifies the disruptive themes driving M&A activity. You can use this report to: Understand the scale and direction of global M&A activity Identify disruptive themes...
-
Thematic Analysis
Pharmaceutical Drug Development Annual Review 2025
This report investigates the year 2025 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Q2 2026 CRO Activity and Intel Report
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2026.
-
Thematic Analysis
Modality Intelligence - From Pipeline to Capital: Strategic Intelligence
Antibodies lead pipeline volume and forecast sales, and drive approvals alongside recombinants, but oligonucleotides are scaling fastest off a smaller base. Maturity and innovation stage, not pipeline size, determine where capital lands next. Capital is consolidating around modalities with proven commercial models, and the cost of entry into mAbs, ADCs, siRNA, and BsAbs is rising across M&A, licensing, and VC alike. Within mAbs and recombinants, capital is rotating out of mature mAb mega-deals and into early-stage ADC and recombinant platform...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.